BEIJING, Sept. 23, 2026 /PRNewswire/ -- Roborock ranked No.1 globally by both unit shipments and sales value among robotic vacuum brands in H1 2026, according to the IDC Worldwide Quarterly Smart Vacuum Robotics Tracker, 2026Q2. The result further strengthens Roborock's sustained leadership in the category, with the company also ranking No.1 globally in cumulative sales value among robotic vacuum brands from Q1 2023 through Q2 2026, according to IDC.
The latest recognition comes as the global robotic vacuum market continues to evolve, with market concentration increasing and competition shifting toward technology innovation, premium products and deeper cleaning experiences. IDC reported that the global robotic vacuum market shipped 7.885 million units in Q2 2026, while leading brands continued to strengthen their positions in the increasingly concentrated market.
Roborock's continued leadership is underpinned by sustained investment in AI-powered perception, intelligent navigation, cleaning performance and robotic mobility. At IFA 2026, the company showcased its latest innovations across indoor and outdoor cleaning, including the Saros 20 Flow, Qrevo Edge 3 Pro, F25 Ultra Steam Gen 2 and F25 Pro Turbo Combo, alongside its expanding outdoor robotics portfolio, including the RockNeo Q2 LiDAR robotic mower and RockAqua P1 robotic pool cleaner.
"Our mission is to give time back to our customers by automating everyday tasks," said Quan Gang, President of Roborock. "Building smarter robots is the means, not the goal. Every minute spent on housework is time taken away from family, passions, and personal well-being."
Roborock's global leadership is supported by continued investment in research and product development. In the first half of 2026, the company recorded RMB 10.084 billion in revenue, up 27.6% year on year, while net profit attributable to shareholders reached RMB 986 million, up 45.6% year on year. R&D investment reached RMB 720 million, representing 7.14% of revenue, supporting continued development across intelligent navigation, AI-powered environmental perception, cleaning systems and robotic mobility.
As robotic cleaning evolves from individual products toward broader, full-scenario applications, Roborock is expanding its robotics portfolio beyond robotic vacuum cleaners. Its sustained leadership in the category provides a foundation for bringing intelligent robotics into more areas of everyday life, with the goal of helping consumers spend less time on routine chores and more time on what matters to them.
Roborock ranked No.1 globally by unit shipments and sales value among robotic vacuum brands in H1 2026. Source: IDC Worldwide Quarterly Smart Vacuum Robotics Tracker, 2026Q2.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Roborock Maintains Global No.1 Position in H1 2026
- Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure.
- With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership position in the life sciences.
- This project will create 12 new jobs and protect 183 existing positions, unlocking new market opportunities and strengthening the sector's competitiveness.
MUMBAI, India, Sept. 30, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), today announced that its Aurora, Canada drug substance site has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialize Ontario-made health technologies for new markets.
With support from the government of Ontario, Piramal Pharma is investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering domestic production of APIs. This project will enhance R&D and clinical API production, ensure the commercial availability of critical drug substances, and support a resilient and globally competitive life sciences industry in Ontario. The investment will create 12 new jobs and protect 183 existing positions.
"We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility," said Peter DeYoung, CEO, Piramal Global Pharma. "This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world. In addition to supporting business growth, this investment will help advance projects focused on sustainability, operational efficiency, and the modernization of our site, reinforcing our commitment to responsible manufacturing and environmental stewardship."
"Through the Life Sciences Scale-Up Fund, our government is ensuring that Ontario businesses are positioned to develop, commercialize and deploy new technologies across the health-care system," said Dawn Gallagher Murphy, Member of Provincial Parliament for Newmarket—Aurora. "With this investment, Piramal will be positioned to turn their latest ideas into market-ready solutions, all while creating good-paying jobs and reinforcing Ontario's position as a global biomanufacturing and life sciences hub."
First launched in 2024, the $24 million LSSUF works in tandem with the government's Health Innovation Pathway to advance the objectives of Phase 2 of Ontario's Life Sciences Strategy and strengthen Ontario's position as a global leader in health innovation. Building on the fund's initial success, the 2026 Ontario Budget invested an additional $24 million to support Ontario companies whose work will accelerate the adoption of innovative technologies in the health-care system and support the province's broader vision of providing connected, convenient care closer to home.
"Ontario's life sciences sector plays a critical role in supporting the discovery and development of innovative medicines and technologies, which is why our government is proud to support local companies as they take their Ontario-made products to the next level," said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. "By investing in Piramal through the Life Sciences Scale-Up Fund, we are scaling up our province's domestic capacity while further positioning Ontario as a leading jurisdiction for life sciences investment for generations to come."
By investing in the Aurora site, the Ontario government is strengthening Ontario's leadership in the life sciences and helping PPS advance next-generation technologies to patients worldwide.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.
For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma | LinkedIn
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
